Great Point Partners (GPP) has acquired Performance Cell Manufacturing (PCM), according to a news release.

PCM, based in San Diego and founded in 2002, is a contract development and manufacturing organization of cell therapy products for biopharmaceutical companies.

As part of the transaction, PCM is changing its name to Cellipont Bioservices.

GPP, based in Greenwich, Conn., is a private investment firm focused on the healthcare industry. Founded in 2003, the firm targets investments in biopharmaceutical supply chain services and products; healthcare services; healthcare information technology-enabled services; and medical devices and diagnostics in businesses operating in the United States, Canada and Western Europe. GPP pursues companies generating between $10 million and $100 million of revenue and $2 million to $12 million of EBITDA, with equity investments ranging from $7 million to $50 million.

Terms of the acquisition were not disclosed